{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T04:52:08Z","timestamp":1769575928091,"version":"3.49.0"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1097\/wnf.0b013e3182a31ec0","type":"journal-article","created":{"date-parts":[[2013,9,17]],"date-time":"2013-09-17T07:43:19Z","timestamp":1379403799000},"page":"151-156","source":"Crossref","is-referenced-by-count":25,"title":["Effectiveness and Tolerability of Switching to Aripiprazole From Risperidone in Subjects With Autism Spectrum Disorders"],"prefix":"10.1097","volume":"36","author":[{"given":"Makoto","family":"Ishitobi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Kosaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiho","family":"Yatuga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mizuki","family":"Asano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanji","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoko","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Omori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michio","family":"Hiratani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akemi","family":"Tomoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20210203","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1517\/14656566.8.11.1579","article-title":"The status of pharmacotherapy for autism spectrum disorders.","volume":"8","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"R4-3-20210203","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.rasd.2010.04.004","article-title":"Psychotropic drug efficacy and side effects for persons with autism spectrum disorders.","volume":"5","year":"2011","journal-title":"Res Autism Spectr Disord"},{"key":"R6-3-20210203","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.rasd.2012.05.007","article-title":"Targeted treatments in autism and fragile X syndrome.","volume":"6","year":"2012","journal-title":"Res Autism Spectr Disord"},{"key":"R7-3-20210203","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pnpbp.2010.10.015","article-title":"Psychopharmacology in autism: an update.","volume":"35","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R10-3-20210203","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/mrdd.20062","article-title":"Novel treatments for autistic spectrum disorders.","volume":"11","year":"2005","journal-title":"Ment Retard Dev Disabil Res Rev"},{"key":"R13-3-20210203","first-page":"723","article-title":"Risperidone in the treatment of behavioral disorders associated with autism in children and adolescents.","volume":"4","year":"2008","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R19-3-20210203","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.pnpbp.2004.06.020","article-title":"Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism.","volume":"28","year":"2004","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R22-3-20210203","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/BF02172092","article-title":"Domains of the Childhood Autism Rating Scale: relevance for diagnosis and treatment.","volume":"24","year":"1994","journal-title":"J Autism Dev Disord"},{"key":"R30-3-20210203","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4088\/PCC.v07n0309","article-title":"A review of pharmacologic strategies for switching to atypical antipsychotics.","volume":"7","year":"2005","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"R31-3-20210203","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/08830738050200071301","article-title":"Aripiprazole in children and adolescents: clinical experience.","volume":"20","year":"2005","journal-title":"J Child Neurol"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/WNF.0b013e3182a31ec0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T07:15:35Z","timestamp":1620976535000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002826-201309000-00003"}},"subtitle":["A Prospective Open-Label Study"],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e3182a31ec0","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}